Export

ATC codes: J05AG01
EMLc
Indication
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified ICD11 code: 1C62.Z
INN
Nevirapine
Medicine type
Chemical agent
List type
Core
Formulations
Oral > Liquid: 50 mg per 5 mL oral solution
Oral > Solid: 200 mg tablet (EML) ; 50 mg tablet (dispersible)
EML status history
First added in 1999 (TRS 895)
Changed in 2002 (TRS 914)
Changed in 2007 (TRS 950)
Changed in 2015 (TRS 994)
Sex
All
Age
Also recommended for children
Age restriction
> 6 weeks
Therapeutic equivalence
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Wikipedia
DrugBank
Summary of evidence and Expert Committee recommendations
The Expert Committee recommended addition of nevirapine 50 mg dispersible tablet formulation to the core list of the EML and EMLc for the treatment of children and adolescents with HIV-1 infection. The Expert Committee agreed on the public health need for paediatric formulations of ART medicines and considered that the proposed formulation of nevirapine represented a rational treatment option for paediatric HIV patients. The Committee noted that this formulation is included in the 2013 WHO guidelines and are categorized by the IATT as an“optimal” paediatric formulation.